Keyword Suggestion
Domain Informations
Xbrane.com lookup results from whois.namesrs.com server:
- Domain created: 2009-10-22T15:11:10Z
- Domain updated: 2023-09-25T12:05:19Z
- Domain expires: 2024-10-22T15:11:10Z 0 Years, 44 Days left
- Website age: 14 Years, 321 Days
- Registrar Domain ID: 1573153801_DOMAIN_COM-VRSN
- Registrar Url: http://www.namesrs.com
- Registrar WHOIS Server: whois.namesrs.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: +46.313011220
- Name server:
- NS-01.FOUREDGE.SE
- NS-02.FOUREDGE.SE
- NS-03.FOUREDGE.SE
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 91.201.60.108
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
Site Inspections
Port Scanner (IP: 91.201.60.108)
Spam Check (IP: 91.201.60.108)
Recent Searched Sites
› Saddleoakestates.com (5 seconds ago) / US
› Dachbud.top (12 seconds ago) / US
› Hndmd.com (16 seconds ago) / US
› Halder.fr (30 seconds ago) / DE
› Sgyxx4qvgkm2hfqtfsxgfzrl2552w5sf75yms5ixo5swfqr5hogq.cdn.ampproject.org (11 seconds ago) / US
› Phisung.aliexpress.com (3 seconds ago) / US
› Rusfond.ru (6 seconds ago) / RU
› Webgap.io (0 seconds ago) / US
› Pptproductivity.com (39 seconds ago) / US
› Vcrochetpatterns.com (27 seconds ago) / LT
› Autorefi.capitalone.com (1 seconds ago) / US
› P4lo.com (47 seconds ago) / DE
› Sofas-and-couches64188.muzwiki.com (36 seconds ago) / US
› Ybmteachers.com (1 seconds ago) / KR
› Proactive-fox-fbtrrd.mystrikingly.com (43 seconds ago) / US
› Mrmsys.org (16 seconds ago) / US
› Xbrane.com (0 seconds ago) / SE
› Profitservice.ru (1 seconds ago) / RU
› Kratomovernight.net (4 seconds ago) / US
› Pilini.bg (1 seconds ago) / BG
Websites Listing
We found Websites Listing below when search with xbrane.com on Search Engine
Patented high yield technology - Xbrane
Xbrane Biopharma changes the date for Interim and Year-end Report. 20 Dec 2021. Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment. 13 Dec 2021. Xbrane has initiated development of two new biosimilar candidates, building an oncology biosimilar portfolio targeting €23 billion in annual reference product sales. 29 Oct 2021 . Xbrane Biopharma releases …
Xbrane.comXbrane – Patented high yield technology
Xbrane Biopharma flyttas upp till Nasdaq Stockholm Mid Cap segment. 13 dec 2021. Xbrane initierar utveckling av två nya biosimilarkandidater och bygger en biosimilarportfölj inom onkologi som adresserar €23 miljarder i årlig försäljning på referensprodukterna. 29 okt 2021. Xbrane Biopharma publicerar delårsrapport för januari – september 2021 . 28 okt 2021. Inbjudan till ...
Xbrane.comXbrane Biopharma Ab email format | Xbrane Biopharma Ab.com ...
Xbrane Biopharma Ab CEO, CFO, CTO, CMO Email and Phone Number Xbrane Biopharma Ab employs 18 employees. View. Andreas vogt. Manufacturing …
Data.aeroleads.comXbrane Biopharma | Company Email | Telephone | Contact ...
Contact details (email, telephone numbers etc.) for Xbrane Biopharma
Pharmacompass.com» Notice of extra general meeting in Xbrane Biopharma AB
Notice of participation at the general meeting shall be sent by regular mail to Xbrane Biopharma AB, Banvaktsvägen 22, 171 48 Stockholm or by e-mail to [email protected]. Upon notification, the shareholder should state their full name, personal identification number or corporate registration number, address and telephone number, and, where applicable, details of representatives, …
Xbrane.comBiogen And Xbrane Enter Into Worldwide …
2 days ago · Martin Åmark, CEO of Xbrane Biopharma AB, further added, “[g]iven their vast development and commercialization experience, we are convinced that Biogen is the best possible partner we could have for Xcimzane.” According to the press release, CIMZIA's primary indications are rheumatoid arthritis, axial spondylarthrosis, psoriasis, and Chron's disease and …
Mondaq.comXbrane Biopharma Ab email format | Xbrane Biopharma AB.com ...
Xbrane biopharma ab uses 0 email formats: 1. (). Enter a name to find and verify an email
Aeroleads.comBiogen and Xbrane Announce Commercialization and License ...
2022-02-07 · Email. Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis ...
Bloomberg.comBiogen (BIIB) and Xbrane Enter Commercialization and ...
2022-02-07 · E-mail Address. StreetInsider.com Top Tickers, 2/7/2022. 1. ULCC 2. AMZN 3. SAVE 4. SPY 5. TPG. 6. FB 7. PTON 8. ON 9. SPOT 10. CRNC. Top News Most Read Special Reports. Wall Street ends lower as ...
Streetinsider.comBiogen licensing deal with Xbrane for Xcimzane biosimilar ...
2022-02-08 · Xbrane Biopharma CEO Martin Åmark said: “Given their vast development and commercialization experience, we are convinced that Biogen is the best possible partner we could have for Xcimzane.” Xcimzane is a monoclonal antibody therapy, currently in preclinical development. Established in 1978, Biogen discovers, develops, and delivers advanced …
Ns-healthcare.comXbrane Pauses Primm Divestment Process :: Generics Bulletin
2022-02-17 · Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
Generics.pharmaintelligence.informa.comCoherus and Xbrane Announce Acceptance of Regulatory ...
2021-10-08 · Coherus and Xbrane Announce Acceptance of Regulatory Submissions for Ranibizumab Biosimilars October 8, 2021 Joshua Weinger ; biosimilar news, Coherus, Lucentis, ranibizumab, Xbrane; On October 1, 2021, Coherus BioSciences announced that FDA has accepted for review Coherus’ BLA for CHS-201, a candidate biosimilar to Lucentis® …
Bigmoleculewatch.comBiogen Reaches Deal With Xbrane For Proposed Biosimilar To ...
2022-02-08 · Feb. 7, 2022, 09:11 PM. (RTTNews) - Biogen Inc. (BIIB) said that it has reached agreement with Xbrane Biopharma to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal ...
Markets.businessinsider.comXbrane Joins Forces With Contract Manufacturer For Cimzia ...
2021-10-07 · Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
Generics.pharmaintelligence.informa.comThe marketing authorization application for Xlucane™ in ...
2021-10-28 · Xbrane announced and implemented at the end of June. After the issue, the total number of shares and votes in the company amounts to 25,039,906. The company’s registered share capital amounts to around SEK 5,613,598. • Xbrane Biopharma was officially certified as a Great Place to Work® by the Great Place to Work® institute. Significant events after the end …
Ipohub.ioBiogen-Xbrane Enter License Agreement For Cimzia ...
2022-02-08 · Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have entered into a license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody, a proposed ...
Finance.yahoo.comXbrane Biopharma Swells In Oncology With Keytruda And ...
2021-12-16 · Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
Generics.pharmaintelligence.informa.comXbrane ingår avtal med Biogen – får förskottsbetalning på ...
2022-02-07 · Xbrane ingår avtal med Biogen – får förskottsbetalning på 8 miljoner dollar. Biosimilarutvecklaren Xbrane Biopharma meddelar att bolaget ingått ett kommersialiserings- och licensavtal med amerikanska Biogen för att utveckla, tillverka och kommersialisera Xcimzane. Uppdaterad: 7 februari 2022, 22:54 Publicerad: 7 februari 2022, 22:21.
Di.seBiogen and Xbrane link up on Cimzia biosimilar
2022-02-10 · Biogen and Xbrane link up on Cimzia biosimilar. 10-02-2022. Comments (0) Print. More on this story. Article STADA and Xbrane advance Lucentis biosimilar candidate. 30-06-2021. Article UCB and Ferring to co-promote Cimzia for Crohn’s disease in USA. 08-07-2020.
Thepharmaletter.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| zhujiyou.com | namesilo.com | -1 Years, -297 Days |
| freshy.com | cloudflare.com | 3 Years, 257 Days |
| dailybeatonline.com | openprovider.com | -2 Years, -169 Days |
| montihouse.com | dynadot.com | -1 Years, -302 Days |
| lozerix.com | reg.ru | -1 Years, -352 Days |
| ollymurs.com | safenames.net | -1 Years, -18 Days |
| abbeal.com | key-systems.net | -1 Years, -356 Days |
| balakplay.com | namecheap.com | 62 Days |
| borgenteam.org | whois.godaddy.com | -1 Years, -364 Days |
| ucmvt.org | namecheap.com | -2 Years, -126 Days |